Regional Analysis
Global CRISPR Genomic Cure Market Regional Insights
- North America is expected to be the largest market for CRISPR genomic cure during the forecast period, accounting for over 45.0% of the market share in 2022. The growth of the market in North America is attributed to the early adoption of new technologies in the region and the presence of a large number of pharmaceutical and biotechnology companies.
- European market is expected to be the second-largest market for CRISPR genomic cure, accounting for over 30.3% of the market share in 2022. The growth of the market in Europe is attributed to the increasing government support for gene-editing research and the presence of a large number of academic institutions.
- Asia Pacific market is expected to be the fastest-growing market for CRISPR genomic cure, with a CAGR of over 25.6% during the forecast period. The growth of the market in Asia Pacific is attributed to the rising prevalence of chronic diseases, the increasing demand for personalized medicine, and the growing government support for gene-editing research.
Figure 1. Global CRISPR Genomic Cure Market Share (%), by Region, 2023
| Geographies covered: |
- North America: U.S. and Canada
- Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
- Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
- Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
- Middle East: GCC Countries, Israel, and Rest of Middle East
- Africa: South Africa, North Africa, and Central Africa
|
U.S.: 
U.K. : 
India : 
